Search by drug, manufacturer, or indication

Displaying 1141 - 1150 of 1165

Afinitor (everolimus)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Pancreatic Neuroendocrine Tumors

Last updated October 11, 2013

Eliquis (apixaban)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Thromboembolic events prevention, (atrial fibrillation)

Last updated October 10, 2013

Replagal (agalsidase alfa)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Fabry Disease

Last updated September 24, 2013

Xtandi (enzalutamide)

Status:

Concluded with an LOI

Manufacturer:

Astellas Pharma Inc.

Indication:

Metastatic Castration-Resistant Prostate Cancer

Last updated September 23, 2013

Fabrazyme (agalsidase beta)

Status:

Concluded with an LOI

Manufacturer:

Sanofi Genzyme Canada

Indication:

Fabry Disease

Last updated September 20, 2013

Jakavi (ruxolintib)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Myelofibrosis

Last updated September 3, 2013

Bystolic (nebivolol)

Status:

Negotiations were not pursued

Manufacturer:

Allergan Inc.

Indication:

Hypertension

Last updated August 22, 2013

Aloxi IV (palonosetron hydrochloride)

Status:

Negotiations were not pursued

Manufacturer:

Eisai Limited

Indication:

Nausea and vomiting (chemotherapy induced) prevention

Last updated August 21, 2013

Aloxi (palonosetron hydrochloride)

Status:

Negotiations were not pursued

Manufacturer:

Eisai Limited

Indication:

Nausea and vomiting (chemotherapy induced) prevention

Last updated August 21, 2013

Sutent (sunitinib malate)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Pancreatic Neuroendocrine Tumors

Last updated August 14, 2013